Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is expected to experience long-term commercial success due to its best-in-class technology in BPH treatment, evidence of management execution, and potential for continued uptake of its HYDROS system across the U.S. and internationally. While competition and pricing pressures may pose risks to its growth, the company is well-positioned in the market and has potential for significant sales contribution in the future. Investors may benefit from purchasing PROCEPT BioRobotics shares due to its strong potential for double-digit sales growth over the next decade in the large and underpenetrated BPH surgical market.

Bears say

PROCEPT BioRobotics is facing significant challenges, including a disappointing quarter and lower revenue guidance, as well as uncertainties around its commercial initiatives and competition in the market. While there are potential positives, such as strong procedure growth and record domestic capital placements, the negative factors and uncertainties lead to a negative outlook for the stock. Additionally, the company's stock is currently bidding down significantly in after-hours trading.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.